Business
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - - Phase 1 SAD and MAD data expected by year-end 2026, with proof-of-concept data in psoriasis patients anticipated in 2027 - WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to bei
About this update from Zenas Biopharma, Inc.
[{"type":"image","alt":"Zenas BioPharma","displaySize":"","headline":null,"caption":"Zenas BioPharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SnwQ6A_D0E0nzqSYhAWCEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1","width":300,"height":117},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/SnwQ6A_D0E0nzqSYhAWCEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1","width":300,"height":117}},"lazy":false},{"type":"text","content":"- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis -","length":194,"tagName":"p"},{"type":"text","content":"- Phase 1 SAD and MAD data expected by year-end 2026, with proof-of-concept data in psoriasis patients anticipated in 2027 -","length":124,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that the first subject has been dosed in the Phase 1 trial of ZB021, a novel potentially best-in-class oral IL-17AA/AF inhibitor.","length":452,"tagName":"p"},{"type":"text","content":"“Dosing the first subject in our Phase 1 trial of ZB021 marks an important milestone for Zenas as we rapidly advance our earlier-stage pipeline and broaden our presence in autoimmune and inflammatory diseases,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. “The IL-17 pathway is well validated across a broad range of rheumatic and dermatologic indications, yet no oral therapies directed toward this pathway are approved or in late-stage clinical development. The strength of this established mechanism may support an accelerated path toward registration-directed trials, and we expect to report initial clinical data by year-end.”","length":653,"tagName"...